Shanghai Junshi Biosciences' (HKG:1877, SHA:688180) unit, Shanghai JunTop Biosciences, received the exclusive license of IAMA-001 nasal spray, according to a Thursday disclosure on the Hong Kong Stock Exchange.
Nanjing JSIAMA Biopharmaceuticals granted the pharmaceutical company the right to conduct research, develop, manufacture, and sell the product in the Greater China region. Both parties will share the interests of the product.
JunTop will pay JSIAMA upfront payments worth 40 million yuan, research and development fees within China of 240 million yuan, and another $150 million for research and development milestones outside China.
JSIAMA will also receive a single-digit percentage sales-based royalties on the annual net sales of the nasal spray, the Chinese pharmaceutical company said.
The company's shares soared more than 10% on the Hong Kong bourse and jumped less than 6% on the Shanghai bourse.
Price (HKD): $13.46, Change: $+1.2, Percent Change: +10.15%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。